Скачать презентацию
Идет загрузка презентации. Пожалуйста, подождите
1
Results No difference in primary endpoint of major CV event (Figure) or in revascularization (25.0% candesartan vs. 26.4% standard therapy, p = 0.41) New onset diabetes in candesartan group (Figure) Drug-related adverse events in candesartan group (p = 0.027), as did study drug discontinuation (p < 0.001) Conclusions Among patients with coronary artery disease and hypertension, treatment with ARB candesartan was not associated with difference in major CV events compared with standard ACE inhibitor therapy without ARB Despite lack of difference in primary endpoint, there did not appear to be harm in ARB group, and there was significant reduction in new onset diabetes, suggesting candesartan may be alternate therapy to ACE inhibitors in this population Results were similar to VALIANT trial, which enrolled patients with acute MI and found that ARBs were non- inferior to ACE inhibitors in reducing CV events HIJ-CREATE % Trial Design: HIJ-CREATE was a randomized trial of candesartan without an ACE inhibitor (n = 1,024) or standard therapy without an ARB (n = 1,025) in patients with coronary artery disease and hypertension. Primary endpoint was major CV events (defined as CV death, MI, unstable angina, heart failure, stroke, or CV hospitalization) through mean 4.2-year follow-up. Candesartan Standard ACE Therapy Major CV Events (HR 0.89, p = 0.19) New Onset Diabetes (p = 0.027) Presented at AHA 2007
Еще похожие презентации в нашем архиве:
